Related Articles
Guillain Barré Syndrome in a multiple myeloma patient after the first course of bortezomib therapy: A case report
CDK5 inhibition in vitro and in vivo induces cell death in myeloma and overcomes the obstacle of bortezomib resistance
Bortezomib overcomes the negative prognostic impact of renal impairment in a newly diagnosed elderly patient with multiple myeloma: A case report
Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation
IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells